U.S., Aug. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07122674) titled '18F-Pentixafor PET in Hematologic Malignancies' on Aug. 07.
Brief Summary: The aim of this study is to evaluate the efficacy of 18F-Pentixafor PET imaging in the diagnosis, staging and response evaluation of hematological malignancies.
Study Start Date: July 01
Study Type: OBSERVATIONAL
Condition:
Hematological Malignancies
Intervention:
DRUG: 18F-Pentixafor
Patients with hematological malignancies receive 55 MBq/kg of 18F-Pentixafor intravenously followed by PET/CT or PET/MR after 60min of injection.
Recruitment Status: RECRUITING
Sponsor: First Affiliated Hospital of Zhejiang University
Published by HT Digital Content Se...